Perrigo To File For $900M Secondary Offering On Wall Street

November 23, 2014 | The Perrigo Company, which produces over-the-counter generic drugs, filed a prospectus to raise $900 million in a secondary offering on Wall Street. According to the company, the funds will be used to help acquire the Belgian over-the-counter drug firm Omega Pharma for $4.5 billion. Some estimates suggest that Perrigo could raise up to $1 billion on the NYSE if book-running managers J.P. Morgan, Barclays and Bank of America and Merrill Lynch agree to buy options. The company, which is headquartered in Ireland and headed by CEO and President Joseph Papa, has a medical development branch in Israel and is the only non-Israeli company listed on the TA-25.